Turning powerful new Complement System insights into innovative treatments

Helping to transform the lives of patients suffering from the eye condition
age-related macular degeneration and other chronic diseases

Turning powerful new Complement System insights into innovative treatments

Helping to transform the lives of patients suffering from the eye condition age-related macular degeneration and other chronic diseases

Geographic atrophy (dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is currently no available treatment. The disease is related to Complement System disorders.

Through an extensive programme of original research we have gained powerful new insights into the ways the Complement System works and how it is dysregulated in age-related macular degeneration.

We are now using these insights to develop a portfolio of treatments for Complement-related diseases including age-related macular degeneration, each with a high clinical need.

World-leading Complement System expertise

Complement Therapeutics is a spin-out from The University of Manchester. Its founders have international reputations and world-leading Complement System expertise.

The company has been created to tackle chronic medical conditions related to Complement System disorders. These conditions include Geographic Atrophy (dry age-related macular degeneration). This is a disease from which some 2.6 million people suffer. It leads to blindness and currently there is no licensed treatment.

In developing therapies, multiple platforms are being pursued, each based on our original patented research and each with the potential to transform lives.

Our platforms


Complement Therapeutics have expertise in gene therapies and protein therapies. Multiple platforms are being pursued.

Gene therapies

Protein therapies

Multiple platforms

Intellectual Property


Our company is based on a strong portfolio of treatments.

  • CTx001: PCT/EP18/065199
  • CTx002: PCT/EP18/065199
  • CTx003: PCT/EP19/062048

We have also developed a Complementome analytics platform:

  • Patent: UK priority application GB2006789.8

Pipeline


In addition to Geographic Atrophy, our pipeline and technologies are relevant for developing treatments for other diseases associated with the Complement System. These include:

  • Kidney diseases (aHUS, DDD, C3G)
  • Systemic diseases (lupus, ischemic reperfusion injury, PNH)
  • Inflammation regulation of the brain

Core Technology Facility
46 Grafton Street
Manchester
M13 9NT
United Kingdom


Created by HTP Digital